+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Non-Alcoholic Fatty Liver Disease. A Practical Guide. Edition No. 1

  • ID: 5225618
  • Book
  • April 2013
  • 324 Pages
  • John Wiley and Sons Ltd

The sharp rise in cases of Non-alcoholic fatty liver disease is fast becoming one of the major concerns for hepatologists worldwide. This comprehensive clinical guide explains how to diagnose NAFLD and manage patients according to the best standards of care. Contributors from the world's leading institutions concentrate on patient care, drawing on their extensive experience.

Note: Product cover images may vary from those shown

List of Contributors, vii

1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1
Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day

2 NAFLD in the community, 17
Leon A. Adams

3 Pathology of NAFLD, 27
Elizabeth M. Brunt and David E. Kleiner

4 The natural history of NAFLD, 37
Paul Angulo

5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46
Isabelle A. Leclercq

6 Diabetes and NAFLD: why is the connection important? 62
Elisabetta Bugianesi

7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71
Giovanni Targher

8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84
Shivakumar Chitturi and Geoffrey C. Farrell

9 Imaging of NAFLD, 93
Takeshi Yokoo, An Tang, and Claude B. Sirlin

10 Non-invasive methods to determine the severity of NAFLD and NASH, 112
Vincent Wai-Sun Wong and Henry Lik-Yuen Chan

11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122
Julia L. Newton and James Frith

12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132
Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne

13 NAFLD, obesity, and bariatric surgery, 149
Philippe Mathurin

14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157
Quentin M. Anstee, Ann K. Daly, and Christopher P. Day

15 NAFLD in children, 171
Ariel E. Feldstein

16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182
Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison

17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192
Janine Graham and Helen L. Reeves

18 NAFLD in Chinese and South Asian people, 206
Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan

19 Non-alcoholic fatty liver disease in Japan, 217
Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh

20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228
Helma Pinchemel Cotrim and Carla Daltro

21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234
Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough

22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248
Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio

23 Metabolic factors and steatosis in patients with hepatitis B and C, 260
Francesco Negro

24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271
Mohammad S. Siddiqui and Arun J. Sanyal

25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284
Anne Catherine Bürgi and Jean-François Dufour

26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293
Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader

Index, 308

Color plate section facing p86

Note: Product cover images may vary from those shown
Geoffrey C. Farrell Australian National University.

Arthur J. McCullough Case Western Reserve University.

Christopher P. Day Institute of Cellular Medicine.
Note: Product cover images may vary from those shown